Indefinite Delivery Contract SPE2DU25D9265

The Defense Logistics Agency (DLA) Troop Support Medical Supply Chain is planning to issue a solicitation for the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) to establish Prime Vendor Contracts for worldwide pharmaceutical support to Defense Health Agency (DHA), Department of Defense (DoD) customers, the United States Coast Guard, Designated Providers, Other Government Agencies, and the US Naval Fleet. The contract will have a 30-month base period and three 30-month option periods, with an estimated total value of $30.3 billion. The solicitation is expected to be issued in March 2024 and remain open for 45 days. Awards will be made on a regional basis, with at least three different contractors to be selected across the North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet line items. Both primary and backup suppliers will provide separate distribution fees for brand/generic and specialty pharmaceuticals to support normal and contingency operations globally.

The resulting Indefinite Delivery Contract (IDC) awarded to DMS Pharmaceutical Group Inc., a woman-owned small business, is valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide.